Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Serono Broadens Research Pipeline With ZymoGenetics Alliance

This article was originally published in The Pink Sheet Daily

Executive Summary

Serono will pay over $81 mil. upfront for access to ZymoGenetics’ therapeutic protein research. The deal includes a license to products based on three proteins that could expand Serono’s presence in inflammation and autoimmune disease.

You may also be interested in...



ZymoGenetics’ rhThrombin Expected To Launch In 2007

Company anticipates recombinant human product could take market share away from competing King biologic.

ZymoGenetics’ rhThrombin Expected To Launch In 2007

Company anticipates recombinant human product could take market share away from competing King biologic.

Novo Nordisk Licenses Factor XIII Portfolio From ZymoGenetics

The company is discussing the pivotal trial program for Factor XIII with FDA following the agreement. Novo Nordisk expects to initiate clinical studies in fibrinolysis-induced bleeding next year.

Topics

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel